Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Magro

Showing results (111-120 of 340) with videos related to

Pageof 34
Sort By:
Vaccines|March 30, 2023
Adherence to Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Two-Year Prospective Portuguese Cohort StudyCandida Abreu, Antonio Martins, Fernando Silva, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 12, 2025
Artificial Intelligence for Clinical Trial Facilitation, Lessons for Inflammatory Bowel Disease: A Scoping ReviewCatherine Le Berre, Vipul Jairath, Remo Panaccione, et al.
Frontiers in Medicine|December 17, 2020
Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence DecisionRogério Sá Gaspar, Beatriz Silva-Lima, Fernando Magro, et al.
Journal of Gastroenterology and Hepatology|April 1, 2018
Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinicianStephan Miehlke, Manuel Barreiro-de Acosta, Gerd Bouma, et al.
Journal of Crohn'S & Colitis|February 16, 2020
Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative ColitisSéverine Vermeire, Milan Lukáš, Fernando Magro, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 10, 2020
Systematic Review and Principal Components Analysis of the Immunogenicity of AdalimumabRodrigo Borrega, Carlos Araújo, Nádia Aguiam, et al.
Therapeutic Advances in Gastroenterology|February 14, 2022
Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide studyMafalda Santiago, Fernando Magro, Luís Correia, et al.
Clinical and Translational Gastroenterology|April 13, 2021
Ileal Crohn's Disease Exhibits Similar Transmural Fibrosis Irrespective of PhenotypeHelena Tavares de Sousa, Irene Gullo, Claudia Castelli, et al.
Pharmacology Research & Perspectives|June 2, 2020
Gut bacterial microbiome composition and statin intake-A systematic reviewAndreia M Dias, Gonçalo Cordeiro, Maria M Estevinho, et al.
Clinical and Translational Gastroenterology|October 23, 2020
Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by PrevalenceMafalda Santiago, Fernando Magro, Luís Correia, et al.
Pageof 34

Showing results (111-120 of 340) with videos related to

Sort By:
Pageof 34
Vaccines|March 30, 2023
Adherence to Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Two-Year Prospective Portuguese Cohort StudyCandida Abreu, Antonio Martins, Fernando Silva, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 12, 2025
Artificial Intelligence for Clinical Trial Facilitation, Lessons for Inflammatory Bowel Disease: A Scoping ReviewCatherine Le Berre, Vipul Jairath, Remo Panaccione, et al.
Frontiers in Medicine|December 17, 2020
Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence DecisionRogério Sá Gaspar, Beatriz Silva-Lima, Fernando Magro, et al.
Journal of Gastroenterology and Hepatology|April 1, 2018
Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinicianStephan Miehlke, Manuel Barreiro-de Acosta, Gerd Bouma, et al.
Journal of Crohn'S & Colitis|February 16, 2020
Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative ColitisSéverine Vermeire, Milan Lukáš, Fernando Magro, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 10, 2020
Systematic Review and Principal Components Analysis of the Immunogenicity of AdalimumabRodrigo Borrega, Carlos Araújo, Nádia Aguiam, et al.
Therapeutic Advances in Gastroenterology|February 14, 2022
Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide studyMafalda Santiago, Fernando Magro, Luís Correia, et al.
Clinical and Translational Gastroenterology|April 13, 2021
Ileal Crohn's Disease Exhibits Similar Transmural Fibrosis Irrespective of PhenotypeHelena Tavares de Sousa, Irene Gullo, Claudia Castelli, et al.
Pharmacology Research & Perspectives|June 2, 2020
Gut bacterial microbiome composition and statin intake-A systematic reviewAndreia M Dias, Gonçalo Cordeiro, Maria M Estevinho, et al.
Clinical and Translational Gastroenterology|October 23, 2020
Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by PrevalenceMafalda Santiago, Fernando Magro, Luís Correia, et al.
Pageof 34